Herantis H1 2023: Progress in the clinic - Redeye

Redeye reviews the case of Herantis in the wake of progress with clinical candidate HER-096 and H1 report. We continue to see an interesting case going forward and are are excited to see that Herantis now again is a clinical stage company.

Länk till analysen i sin helhet: https://www.redeye.se/research/939231/herantis-h1-2023-progress-in-the-clinic?utm_source=finwire&utm_medium=RSS